Thank you, Mr. Chair.
Pierre, I'm going to come back to you and continue the momentum here in terms of thank yous. Of course, you know I have a son with autism, and the scientists behind the autism genome project in Canada are among the world leaders in genetic research on autism.
I had a chance to visit Steve Scherer in Toronto, a second time that I've had the chance to tour his facility. The first time around we actually did it with my son and daughter and my whole family, but I had a chance a few weeks back to see him. It was pretty exciting, with them moving into a new building there soon, and it's exciting to hear about the phenomenal research that they're doing.
As it relates to the study that we're doing right now on IP, it seems to me that the application benefit of IP, dealing with a company like RIM, is very tangible—well, maybe not very tangible, but as tangible as IP can get in terms of understanding that benefit—but with something like what they're doing at the autism genome project, I think it's a little less tangible. Maybe you could speak to some of the practical application of IP with the work that Steve's doing. What does it look like, and how is the value of the IP recognized?